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T cell education 
dictates function
How a young T cell is educated may dictate its 
future function, according to a new report by Li 
et al. (page 2145).
Young T cells receive survival signals through 
their T cell receptors during development. These 
signals are normally provided by epithelial cells in the 
thymus. But recent reports show that CD4+ 
thymocytes also signal to each other.
When stimulated by antigen, epithelium-educated 
CD4+ thymocytes can become helper T cells of all 
varieties—T helper (Th)-1, Th2, or Th17 cells—
depending largely on the surrounding cytokines. But 
self-educated thymocytes, Li et al. now find, fail to 
make this lineage choice. These cells rapidly generated 
both interferon (IFN)-γ and interleukin (IL)-4, even 
when stimulated under conditions that normally inhibit 
IL-4 production. A ready-to-fire IL-4 locus and 
preformed  IL-4 mRNA in the developing cells 
explained their tendency to continue synthesizing IL-4.
Mice whose thymocytes were forced to signal to 
each other to survive were less likely to develop allergic 
inflammation than were mice whose T cells developed 
normally. This protective effect might be due, the 
authors speculate, to the suppression of pro-allergic IL-4 
by the IFNγ produced by these cells. Thus, people who 
have more self-educated T cells may be less allergy 
prone. But assessing the relative numbers of the two cell 
types in humans is difficult, as distinguishing surface 
markers have yet to be identified.
The team is now investigating how T cells decide 
between a thymocyte- and an epithelial cell–based 
education and how thymocyte-to-thymocyte signals 
set the cells up for an IL-4–producing future. 
A T cell transcription factor favors short-term 
benefits over long-term stability, according to a new 
study by Intlekofer et al. (page 2015).
Long-term protection against pathogens by 
CD8+ T cells is due to a self-renewing population of 
central memory (TCM) cells that circulate in the 
lymph nodes. When they see their target antigen, 
these cells first rapidly proliferate, become cytotoxic, 
and then head out to the periphery to fight the 
invaders. A faster attack mode is provided by effector 
memory T (TEM) cells, which are already in the 
periphery, but these cells quickly die out.
Memory T cell development requires a 
transcription factor called T-bet. Intlekofer et al. 
now find that mice lacking T-bet have plenty of 
TCM cells but lack the TEM pool. In normal mice, 
only the TEM cells expressed T-bet, suggesting that 
T-bet skews the balance between the two 
populations by driving the differentiation of 
activated CD8+ T cells into TEM cells.
CD8+ memory T cell development also requires 
signals from CD4+ T cells. The team found that 
these signals favored the growth of CD8+ TCM cells. 
Mice that lacked CD4+ T cells therefore had higher 
numbers of TEM cells than TCM cells. This expanded 
TEM population had high levels of T-bet protein. 
Deletion of T-bet corrected this defect by restoring 
the numbers of self-renewing cells. 
Following the trail 
from COX-2 to clotting
On page 2053, Ghosh et al. reveal how antiinflammatory COX-2 
inhibitors cause dangerous cardiac side effects. COX-2, they find, 
is needed to shut off an important clotting protein.
COX-2 is produced during infection and injury by the endothelial 
cells that line blood vessels. The enzyme converts a cellular lipid 
known as arachidonic acid into lipids that instigate fever, pain, and 
other uncomfortable hallmarks of inflammation.
COX-2 inhibitors such as Vioxx were popular antiinflammatory 
drugs until some users began to suffer serious side effects such as 
heart attack and stroke.
Ghosh et al. now find that the normally cardioprotective effect of 
COX-2 stems from its metabolic conversion not of arachidonic acid, 
but of other substrates: the endocannabinoids. Byproducts of these 
lipids, they found, activated a nuclear receptor and transcription 
factor, PPARδ, that suppressed the gene for tissue factor (TF)—
a protein that activates blood clotting. Mice that were given COX-2 
inhibitors had high levels of TF that could then be decreased by 
activating PPARδ. The side effects triggered by the COX-2 inhibitors 
in humans may thus be due to the overproduction of TF.
COX-2’s anticlotting role probably keeps injured vessels free 
of clots while the damage is being repaired. The team is now 
investigating whether patients who have adverse reactions to the 
drugs have defects in TF or other clotting genes. 
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The transcription 
factor T-bet is 
expressed mainly 
in TEM cells.
A COX-2 inhibitor (right) increases the expression of tissue factor (red) 
in heart vessels (arrows).